Key Highlights: Implications: Mankind Pharma’s exclusive agreement with Chongqing Chenan adds two insulin analogues to its India portfolio, strengthening its position in the injectable diabetes segmen...
Key Highlights: Implications: The USFDA’s EIR and VAI classification provide regulatory closure for Strides Pharma’s Bengaluru facility following the five observations issued during the May 2026 inspe...
Key Highlights: Implications: Hearzap’s acquisition of Amplifon India’s hearing care business instantly adds ~240 points of sale (including 115 directly operated centres), clinical teams and an establ...
Key Highlights: Implications: Piramal Pharma’s move to 74% ownership of Yapan Bio for ₹76 crore turns the Hyderabad CDMO into a subsidiary, giving Piramal tighter control over Yapan’s process developm...
Key Highlights: Implications: Optimus Pharma’s DCGI approval for Tapinarof Cream 1% gives India its first locally manufactured, non‑steroidal topical for adult plaque psoriasis, offering dermatologist...
Key Highlights: Implications: The Elephas–Neuberg partnership brings a functional, live‑tissue test for immunotherapy response into India’s mainstream diagnostics, giving oncologists an&nb...
Key Highlights: Implications: Biodeal’s ₹385 crore raise gives it the capital to scale up manufacturing, add new products, and enter more regulated markets, which should help it win bigger, longer-ter...
Key Highlights: Implications: For Novartis India, bringing these brands back in‑house supports a more controlled go‑to‑market under new PE ownership and aligns with its plan to insta...
Key Highlights: Implications: By embedding dynamic QR codes and invoice-linked payment links with automatic bill‑by‑bill reconciliation, the solution can materially cut cash handling, spee...
Key Highlights: Implications: The deal adds ~$90–100 million of annualized revenue visibility from 2029, diversifies Gland’s customer base, and strengthens its credibility as a o...